A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Subjects With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs SAGE 217 (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms MOUNTAIN
- Sponsors Sage Therapeutics
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.
- 07 Jan 2019 According to a SAGE Therapeutics media release, the comapny is expecting to present topline results from this study in 2020.
- 12 Sep 2018 Status changed from planning to not yet recruiting.